Introduction {#section1-1536012120927609}
============

The cell surface purinergic receptors (purinoceptors) are plasma membrane proteins found in nearly all mammalian tissues including the central nervous system (CNS).^[@bibr1-1536012120927609]^ The history of the purinergic receptors goes back to early 20th century when, for the first time, an observation was made that purines effected cardiovascular physiology.^[@bibr2-1536012120927609]^ Almost half a century later, these receptors were classified based on their endogenous ligands into P1 and P2 categories.^[@bibr3-1536012120927609]^

P1 or adenosine receptors (ARs) are a family of G protein--coupled receptors (GPCRs) with 4 subtypes: A~1~, A~2A~, A~2B~, and A~3~. P2 receptors are subgrouped into the ligand-gated ion channel receptors P2X with 7 receptor subtypes: P2X~1~, P2X~2~, P2X~3~, P2X~4~, P2X~5~, P2X~6~, P2X~7~, and P2Y, which are G protein-coupled metabotropic receptors with 8 subtypes: P2Y~1~, P2Y~2~, P2Y~4~, P2Y~6~, P2Y~11~, P2Y~12~, P2Y~13~, and P2Y~14~ ([Figure 1](#fig1-1536012120927609){ref-type="fig"}).^[@bibr4-1536012120927609]^ Burnstock has recently published an excellent review article on purinergic receptors, their distributions, and functions revealing the importance of these receptors in physiological system.^[@bibr5-1536012120927609]^ Purinergic receptors play major roles in CNS disorders including Alzheimer disease (AD), Parkinson disease (PD), Huntington disease (HD), frontotemporal dementia (FD), amyotrophic lateral sclerosis (ALS), multiple scleroses (MS), traumatic brain injury (TBI), stroke, cerebral ischemia, epilepsy, psychiatric diseases, sleep disorder, and neuropathic pain.^[@bibr1-1536012120927609],[@bibr3-1536012120927609],[@bibr6-1536012120927609],[@bibr7-1536012120927609]^

![Purinergic receptor subfamilies and their endogenous ligands.](10.1177_1536012120927609-fig1){#fig1-1536012120927609}

In the CNS, adenosine 5′-triphosphate (ATP), an energy source for neurons and glial cells, also acts as an extracellular purinergic signaling molecule that controls communication between brain cells.^[@bibr8-1536012120927609]^ The steady state concentration of cytosolic ATP is high, ranging between 5 and 10 mM, and very low (nM) in the extracellular space.^[@bibr9-1536012120927609]^ Under pathological conditions and CNS insults such as trauma, ischemic stroke, epileptogenic seizures, cellular stress, neuroinflammation, and neurodegenerative disorders, high concentration of ATP is released to the extracellular region as a danger signal creating a cascade of events that eventually damages the neurons.^[@bibr10-1536012120927609],[@bibr11-1536012120927609]^

High level of extracellular ATP from the damaged cells enforces microglia to undergo chemotaxis to the site of injury in order to remove cell debris from these sites.^[@bibr12-1536012120927609]^ Microglial activation^[@bibr13-1536012120927609]^ results in upregulation of P2X~4~ and P2X~7~ ^[@bibr14-1536012120927609],[@bibr15-1536012120927609]^ and downregulation of P2Y~12~ receptor expression.^[@bibr16-1536012120927609]^ This balance between the expression of P2X~4~, P2X~7~, and P2Y~12~ receptors dictate the destiny of microglia.^[@bibr17-1536012120927609]^ A relative expression levels of P2X~4~ and P2X~7~ receptors are positive indicator of microglial activation, while P2Y~12~ receptor is a negative predictor.^[@bibr18-1536012120927609]^ Additionally, upon release of the large amount of ATP (hundreds of μmol), P2Y~1~ and P2X~7~ receptors facilitate movement of ramified microglia to the damage site, while P2Y~6~ receptor, a normally expressed receptor on the activated microglia, intervenes the process of phagocytosis.^[@bibr3-1536012120927609],[@bibr19-1536012120927609]^ Furthermore, extracellular ATP can be converted to adenosine via ectonucleotidases CD39 and CD73 that are present in microglia^[@bibr20-1536012120927609]^ and in turn activates ARs as well.^[@bibr21-1536012120927609],[@bibr22-1536012120927609]^

While novel ligands of some purinergic receptors are currently used as pharmacological tools to define and modify actions of these receptor subtypes in the CNS,^[@bibr23-1536012120927609]^ there is still a growing need to clearly understand these receptors' roles in the brain, specifically as it relates to neuroinflammation and neurodegeneration. Positron emission tomography (PET) imaging has advanced our understanding of the functions of purinergic receptors in healthy and pathological brains.^[@bibr24-1536012120927609],[@bibr25-1536012120927609]^ Herein, we have reviewed the significance of the purinergic receptors in the CNS and accumulated a comprehensive list of the existing PET radioligands that have been used as tools for understanding the functions of these receptors.

Adenosine, Receptors and Functions in the CNS {#section2-1536012120927609}
=============================================

Adenosine has been widely recognized as an inhibitory modulator of the CNS.^[@bibr26-1536012120927609]^ It acts as a homeostatic modulator at synapses^[@bibr26-1536012120927609],[@bibr27-1536012120927609]^ and participates in neurotransmitter release,^[@bibr28-1536012120927609]^ neuronal excitability, synaptic plasticity,^[@bibr29-1536012120927609]^ and local inflammatory processes.^[@bibr30-1536012120927609],[@bibr31-1536012120927609]^ Adenosine is complicated in neurobiology of learning and memory^[@bibr29-1536012120927609],[@bibr32-1536012120927609],[@bibr33-1536012120927609]^ by overstimulating the *N*-methyl-[d]{.smallcaps}-aspartic acid (NMDA) receptors^[@bibr34-1536012120927609],[@bibr35-1536012120927609]^ that influence long-term potentiation (LTP) and long-term depression (LTD).^[@bibr29-1536012120927609]^ Additionally, adenosine participates in modulation of neurotransmissions exerted by dopamine (DA) and acetylcholine (Ach).^[@bibr36-1536012120927609][@bibr37-1536012120927609][@bibr38-1536012120927609][@bibr39-1536012120927609][@bibr40-1536012120927609][@bibr41-1536012120927609][@bibr42-1536012120927609][@bibr43-1536012120927609][@bibr44-1536012120927609][@bibr45-1536012120927609][@bibr46-1536012120927609][@bibr47-1536012120927609]-[@bibr48-1536012120927609]^ Consumption of drugs of abuse and psychostimulants, either acutely or chronically, has shown to modify adenosine level in the brain.^[@bibr49-1536012120927609]^ As such, a more clear understanding of the involvement of adenosine signaling pathway during addiction might help to explore potential treatments for substance use dependence.^[@bibr50-1536012120927609]^ Several reports have indicated the involvement of adenosine in neuropathological conditions including stroke,^[@bibr51-1536012120927609],[@bibr52-1536012120927609]^ epilepsy,^[@bibr53-1536012120927609]^ PD,^[@bibr54-1536012120927609][@bibr55-1536012120927609][@bibr56-1536012120927609]-[@bibr57-1536012120927609]^ and other neurodegeneration disorders.^[@bibr31-1536012120927609]^

Extracellular adenosine binds to its 4 receptor subtypes A~1~, A~2A~, A~2B~, and A~3~ to exert its effect in the CNS.^[@bibr30-1536012120927609]^ A~1~R and A~2A~R have high affinities of 70 and 150 nM, respectively, while A~2B~R and A~3~R have a distinctly lower affinities of 5100 and 6500 nM, respectively, for adenosine.^[@bibr58-1536012120927609]^ All ARs are present on neurons,^[@bibr52-1536012120927609]^ astrocytes,^[@bibr59-1536012120927609]^ oligodendrocytes,^[@bibr60-1536012120927609]^ and microglia.^[@bibr61-1536012120927609]^

In the brain, A~1~ and A~2A~ are the major ARs.^[@bibr58-1536012120927609]^ A~1~ receptor, the most abundant subtype, is widely distributed in the cortex, hippocampus, and cerebellum, while A~2A~ receptor is mainly localized in the striatum and olfactory bulb.^[@bibr30-1536012120927609]^ Presynaptically, A~1~ and A~2A~ interact with adenosine to modulate the release of neurotransmitters.^[@bibr62-1536012120927609]^ Postsynaptically, adenosine decreases cellular excitability through activation of A~1~Rs or inhibition of A~2A~Rs.^[@bibr63-1536012120927609]^ Thus, A~1~Rs impose an inhibitory brake on excitatory transmission, while A~2A~ receptors engage in promoting excitatory effect.^[@bibr64-1536012120927609]^ In general, A~1~R is considered a neuroprotective and A~2A~ receptor is designated as a neurodegenerative receptor.^[@bibr65-1536012120927609]^ Consequently, adenosine mainly effects brain functions through interaction with these 2 receptors, A~1~ and A~2A~,^[@bibr64-1536012120927609]^ and a fine balance between inhibitory action of A~1~ and excitatory function of A~2A~ receptors influences the neuromodulatory effect of adenosine.

Adenosine receptors undergo different activities during neurodegeneration progression.^[@bibr66-1536012120927609]^ While both A~1~ and A~2A~ receptors have shown upregulation in the frontal cortex,^[@bibr67-1536012120927609]^ the A~1~R expression was reduced in hippocampus, specifically in dentate gyrus, and in CA1, but not in CA3 region.^[@bibr68-1536012120927609]^ Additionally, studies of brain of patients with AD have revealed reduction of striatal A~1~Rs in this population.^[@bibr31-1536012120927609]^ Several studies have shown that both A~1~R and A~2A~R may be involved in metabolism of amyloid β (Aβ) protein and A~1~ agonists and A~2A~ antagonists might serve as an effective therapy for treating patients with AD.^[@bibr69-1536012120927609],[@bibr70-1536012120927609]^ Moreover, there are some evidences that support the cross talk between A~1~Rs and A~2A~Rs in other age-related disorders.^[@bibr71-1536012120927609][@bibr72-1536012120927609]-[@bibr73-1536012120927609]^

Both A~1~ and A~2A~ receptors are also expressed in endothelial cells of the primary human brain, suggesting that modulation of these receptors can alter blood--brain barrier (BBB) and result in abnormal brain permeability that could interfere with drug delivery into the CNS.^[@bibr74-1536012120927609]^

Provided the roles of A~1~ and A~2A~ receptors in brain pathologies, the availability of scientific tools such as specific PET radioligands for evaluation of these receptors functions under normal and pathophysiological conditions would be desirable and could help elucidate novel therapeutic strategies.^[@bibr75-1536012120927609]^

Adenosine A~1~R and Functions in the CNS {#section3-1536012120927609}
----------------------------------------

A~1~ is the most abundant AR subtype in the brain with broad distribution in neurons of the cortex, hippocampus, and cerebellum.^[@bibr31-1536012120927609],[@bibr58-1536012120927609]^ Several studies have shown that activation of adenosine A~1~R promoted neuroprotection, induced sedation, reduced anxiety, inhibited seizures,^[@bibr76-1536012120927609]^ and reduced A~1~R exacerbated neuronal damage.^[@bibr58-1536012120927609]^ Significant reduction in A~1~R expression was detected in layers of the dentate gyrus in the brain of AD subjects,^[@bibr68-1536012120927609],[@bibr77-1536012120927609]^ providing evidence that A~1~R agonists might be an effective therapy for treatment of AD even at late stages of the disease.^[@bibr78-1536012120927609]^ Additionally, A~1~R agonists or adenosine reuptake inhibitors have shown to decrease the extent of brain damage in most brain injuries.^[@bibr78-1536012120927609],[@bibr79-1536012120927609]^ There are evidences of increased microglial proliferation; enhanced matrix metalloproteinase 12 (MMP-12) expression, inducible nitric oxide synthase, and pro-inflammatory interleukin-1β (IL-1β); and exacerbated demyelination in MS and neuronal injury in A~1~R knockdown animal models.^[@bibr80-1536012120927609],[@bibr81-1536012120927609]^ The positive effect of A~1~Rs activation in the CNS suggests that this receptor could be one of the most promising targets for the development of novel drugs with neuroprotective effect for the treatment of neurological and psychiatric disorders.^[@bibr69-1536012120927609]^

Several A~1~R agonist have been reported to date; most of them have only minimal brain penetration. A nonselective agonist MRS5474 has shown antidepressant and anticonvulsant activities.^[@bibr82-1536012120927609]^ While not optimum to fully map all the functions of the A~1~R in the brain, several ^[@bibr11-1536012120927609]^ C and ^[@bibr18-1536012120927609]^ F PET radioligands of the receptor have been evaluated for imaging of the A~1~R in the brain as described herein.

### \[^[@bibr11-1536012120927609]^C\] PET radioligands of adenosine A~1~R {#section4-1536012120927609}

As shown in [Figure 2](#fig2-1536012120927609){ref-type="fig"}, several ^[@bibr11-1536012120927609]^ C PET radioligands of the A~1~R have been developed and tested thus far. The first PET radiotracer was developed by ^[@bibr11-1536012120927609]^ C radiolabeling of the xanthene-derived A~1~R antagonist KF15372, \[^[@bibr11-1536012120927609]^ C\]KF15372, and showed a specific and reversible brain uptake but an unacceptable high fraction of nonspecific binding that limited its use in preclinical evaluation of the A~1~R.^[@bibr83-1536012120927609],[@bibr84-1536012120927609]^ \[^[@bibr11-1536012120927609]^ C\]MPDX, another analog of A~1~R antagonist KF15372, was developed to measure regional A~1~R densities in the brain of rodent and in patients with diffuse axonal injury, a model for TBI.^[@bibr85-1536012120927609]^ It detected an increase in A~1~R expression in areas surrounding the injuries in the brain, emphasizing on neuroprotective and neuromodulatory effects of A~1~R in TBI.^[@bibr85-1536012120927609]^ Moreover, \[^[@bibr11-1536012120927609]^ C\]MPDX was also used to investigate the cerebral density of A~1~Rs in early stages of PD and showed a higher binding potential in the temporal lobe of the patients with PD compared to the healthy controls.^[@bibr86-1536012120927609]^ Similarly, \[^[@bibr11-1536012120927609]^ C\]MPDX was used for mapping of the A~1~Rs in the brain of aged human compared to the young subjects and showed a significantly lower BP~ND~ in the frontal, temporal, occipital, parietal cortices, and thalamus of aged subjects.^[@bibr87-1536012120927609]^ \[^[@bibr11-1536012120927609]^ C\]MPDX is currently the most widely used PET agent for imaging the A~1~Rs in human brain.^[@bibr83-1536012120927609],[@bibr85-1536012120927609]^ Interestingly, \[^[@bibr11-1536012120927609]^ C\]MPDX was employed to identify the selective antagonists (DPCPX and caffeine) and agonist (*N*6-cyclopentyladenosine \[CPA\]) binding sites on the A~1~Rs and suggested that different ligands (agonists and/or antagonists) bind to A~1~Rs allosterically.^[@bibr88-1536012120927609]^

![Structures of the adenosine A~1~ receptor \[^11^C\] PET radioligands: \[^11^C\]KF15372, \[^11^C\]MPDX, \[^11^C\]FR194921, and \[^11^C\]MMPD. PET indicates positron emission tomography.](10.1177_1536012120927609-fig2){#fig2-1536012120927609}

The first nonxanthine ^11^C PET ligand of A~1~ R was \[^11^C\]FR194921, an analog of a potent A~1~R antagonist FR194921 (K~i~ = 2.9 nM).^[@bibr89-1536012120927609],[@bibr90-1536012120927609]^ The PET imaging with \[^11^C\]FR194921 showed selective accumulation of A~1~Rs in the hippocampus, cerebral cortex, striatum, thalamus, and cerebellum of the rat brain.^[@bibr89-1536012120927609]^ However, the specific binding of \[^11^C\]FR194921 was not as high as expected.^[@bibr89-1536012120927609]^ Recently, a highly potent partial A~1~R agonist 2-amino-4-(3-methoxyphenyl)-6-(((6-methylpyridine-2-yl)methyl)thio)pyridine-3,5-dicarbonitrile was labeled with ^11^C to produce \[^11^C\]MMPD and showed brain uptake that was consistent with A~1~R.^[@bibr91-1536012120927609]^ \[^11^C\]MMPD is currently under further evaluation for participation of A~1~R in sleep mechanisms.^[@bibr91-1536012120927609]^

### \[^18^F\] PET radioligands of adenosine A~1~R {#section5-1536012120927609}

Few ^18^F PET radioligands have been developed and evaluated for imaging of the A~1~R as shown in [Figure 3](#fig3-1536012120927609){ref-type="fig"}. Of these, \[^18^F\]CPFPX has shown high affinity and selectivity for A~1~R^[@bibr6-1536012120927609],[@bibr92-1536012120927609]^; however, due to the high in vivo metabolism, this radiotracer exhibited a short biological half-life of only about 10 minutes.^[@bibr84-1536012120927609]^ Despite this fact, \[^18^F\]CPFPX has been used for imaging of A~1~Rs in the human brain^[@bibr93-1536012120927609]^ and is currently a standard PET radioligand for evaluation of the A~1~R density in CNS disorders such as sleep--wake research.^[@bibr84-1536012120927609],[@bibr94-1536012120927609][@bibr95-1536012120927609]-[@bibr96-1536012120927609]^

![Structures of the adenosine A~1~ receptor \[^18^F\] PET radioligands: \[^18^F\]CPFPX, \[^18^F\]CBCPM, and \[^18^F\]CPMMCB. PET indicates positron emission tomography.](10.1177_1536012120927609-fig3){#fig3-1536012120927609}

In order to improve metabolic stability inherent in \[^18^F\]CPFPX, two additional fluorinated PET analogs \[^18^F\]CBCPM and \[^18^F\]CPMMCB were developed and tested.^[@bibr84-1536012120927609]^ In vitro autoradiographic studies of rat brain slices with \[^18^F\]CBCPM and \[^18^F\]CPMMCB revealed accumulation of both compounds in regions known to have a high A~1~R expression. However, in vitro metabolite studies using human liver microsomes identified comparable metabolic instabilities for these radioligands, similar to that of the parent ligand \[^18^F\]CPFPX.^[@bibr84-1536012120927609]^

Importantly, both \[^11^C\]MPDX or \[^18^F\]CPFPX are inverse agonist of the A~1~R. \[^11^C\]MPDX did not compete with either endogenous or exogenous agonist in receptor binding but did show an increased binding potential without enhanced tracer delivery to the brain.^[@bibr88-1536012120927609]^ Despite stated limitations, these tracers^[@bibr85-1536012120927609]^ have presented promising imaging tools for mapping of A~1~R in the brain^[@bibr86-1536012120927609],[@bibr87-1536012120927609],[@bibr96-1536012120927609]^. A list of all aforementioned A~1~R PET radioligands is presented in [Table 1](#table1-1536012120927609){ref-type="table"}.

###### 

Adenosine A~1~ Receptor PET Ligands for CNS Studies.

![](10.1177_1536012120927609-table1)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Receptor   PET ligand          Affinity (nM)     Status                                                                                                                                                                                                    References
  ---------- ------------------- ----------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------
  A~1~R      \[^11^C\]KF15372    3.0 (K~i~)        Exhibited high fraction of nonspecific binding that limited its use in preclinical evaluation of the A~1~ receptor.                                                                                       ^[@bibr83-1536012120927609]^

  A~1~R      \[^11^C\]MPDX       4.2 (K~i~, r)     Used to study A~1~R function in patients with AD. Studied in patients with TBI and in patients with early stages of PD. Currently, the most widely used PET agent for imaging the A~1~R in human brain.   ^[@bibr85-1536012120927609][@bibr86-1536012120927609]-[@bibr87-1536012120927609]^

  A~1~R      \[^11C^\]FR194921   4.96 (K~i~, r)\   Showed acceptable BBB permeability, but relatively low specific binding in the rodent brain that limited its further use.                                                                                 ^[@bibr89-1536012120927609],[@bibr90-1536012120927609]^
                                 2.91 (K~i~, h)                                                                                                                                                                                                              

  A~1~R      \[^11^C\]MMPD       0.49 (K~i~, r)\   Exhibited an A~1~R partial agonist activity. Showed BBB permeability. Currently under evaluation in sleep mechanisms.                                                                                     ^[@bibr91-1536012120927609]^
                                 0.8 (K~i~, h)                                                                                                                                                                                                               

  A~1~R      \[^18^F\]CPFPX      3.49 (K~i~, r)\   Used to study sleep deprivation in humans. Fast metabolic degradation. An inverse agonist of the A~1~ receptor.                                                                                           ^[@bibr84-1536012120927609],[@bibr93-1536012120927609][@bibr94-1536012120927609][@bibr95-1536012120927609]-[@bibr96-1536012120927609]^\
                                 0.18 (K~i~, h)\                                                                                                                                                                                                             
                                 4.4 (K~d~, r)\                                                                                                                                                                                                              
                                 1.26 (K~d~, h)                                                                                                                                                                                                              

  A~1~R      \[^18^F\]CBCPM      8.86 (K~i~)       Exhibited low nonspecific binding. Metabolic degradation rate similar to \[18\]CPFPX.                                                                                                                     ^[@bibr84-1536012120927609]^

  A~1~R      \[^18^F\]CPMMCB     3.73 (K~i~)       Exhibited low nonspecific binding. Metabolic degradation rate similar to \[18\]CPFPX.                                                                                                                     ^[@bibr84-1536012120927609]^
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AD, Alzheimer disease; A~1~R, adenosine A~1~ receptor; BBB, brain--blood barrier; CNS, central nervous system; h, human; m, mice; PD, Parkinson disease; PET, positron emission tomography; r, rat.

Adenosine A~2A~R and Functions in the CNS {#section6-1536012120927609}
-----------------------------------------

Highly expressed in the basal ganglia, A~2A~Rs specially reside on GABAergic neurons of the striatum.^[@bibr58-1536012120927609]^ These receptors are also expressed at low level in hippocampus, cortex, and other brain regions, and the extrastriatal increase in A~2A~Rs has been detected in pathological challenge models and animal models of neuroinflammation.^[@bibr97-1536012120927609]^ Several studies have revealed an increased level of A~2A~R expression in hippocampal neurons of patients with AD and in animal models of cognition.^[@bibr98-1536012120927609],[@bibr99-1536012120927609]^ The same studies reported that inhibition or genetic deletion of A~2A~ receptors enhanced memory function in the brain.^[@bibr100-1536012120927609]^ A~2A~ receptors are also expressed in areas of the brain that is rich in DA,^[@bibr101-1536012120927609]^ providing a possibility of being considered as a target for developing drugs that prevent addiction.^[@bibr102-1536012120927609]^

Inhibition of A~2A~R has resulted in a complete shift of LTD to LTP, supporting a major role of A~2A~Rs in cognitive deficits.^[@bibr103-1536012120927609]^ Inhibition of A~2A~R has also been promising in reduction of excitotoxicity in neurons^[@bibr104-1536012120927609],[@bibr105-1536012120927609]^ and in movement diminished motor symptoms in PD.^[@bibr54-1536012120927609],[@bibr55-1536012120927609],[@bibr106-1536012120927609][@bibr107-1536012120927609][@bibr108-1536012120927609][@bibr109-1536012120927609][@bibr110-1536012120927609]-[@bibr111-1536012120927609]^ Additionally, in vitro studies of A~2A~R antagonists have shown to prevent Aβ-induced neurotoxicity and synaptotoxicity,^[@bibr99-1536012120927609],[@bibr100-1536012120927609]^ while A~2A~ receptor agonists increased Aβ production.^[@bibr100-1536012120927609]^ However, study of APP/PS1 mice treated with A~2A~ receptor antagonist istradefylline, an anti-Parkinson drug, showed an increase in Aβ~42~ accumulation in cortical, but not in the hippocampal neurons.^[@bibr112-1536012120927609]^ The underlying relationship between amyloid deposition, AD progression, and adenosine remains unclear and require more clarification.^[@bibr97-1536012120927609],[@bibr113-1536012120927609],[@bibr114-1536012120927609]^ Nevertheless, there is an indication that activation A~2A~ receptor can result in microglia activation and antagonists of A~2A~ receptor can reverse this process.^[@bibr115-1536012120927609]^ Some studies have suggested that A~2A~ receptor inhibition might also contribute to control of astrogliosis as well,^[@bibr116-1536012120927609]^ and selective elimination of A~2A~ receptors from astrocytes has resulted in memory improvement in animal models of AD.^[@bibr113-1536012120927609]^ Therefore, in addition to microglia, astrocytes might also be a responsible culprit, associating A~2A~ receptor with neuroinflammatory and neurodegenerative diseases.

Interestingly, excitotoxicity prevention by the A~2A~ receptor antagonist appears to be time dependent, and while A~2A~ receptor antagonist SCH58261 completely blocked the induced glutamate release in rat striatum,^[@bibr117-1536012120927609]^ its effect was reversed 2 weeks after the treatment.^[@bibr105-1536012120927609]^ Remarkably, this spontaneous glutamate release in response to SCH58261 treatment was different in young rats compared to the aged ones.^[@bibr104-1536012120927609]^ Additionally, recent study suggested that, although A~2A~ receptor antagonists initially protected against transient ischemic injury, this protective effect disappeared 7 days after ischemia and despite continued treatment with the antagonist.^[@bibr118-1536012120927609]^

Application of pharmacological tools of the A~2A~ receptors have shown a significant benefit in treating several CNS disorders,^[@bibr119-1536012120927609]^ and thus, PET imaging of the A~2A~ receptors has been useful to study in vivo expression of A~2A~ receptors in normal and under pathophysiological brains.

### \[^11^C\] PET radio ligands of adenosine A~2A~R {#section7-1536012120927609}

Several ^11^C radioligands of the A~2~R have been developed for PET imaging of this receptor as shown in [Figure 4](#fig4-1536012120927609){ref-type="fig"}. These most studied ligands are 2 xanthine-derived compounds, \[^11^C\]TMSX (\[^11^C\]KF18446) and \[^11^C\]KF21213, and 2 nonxanthene compounds, \[^11^C\]SCH442416 and \[^11^C\]Preladenant.^[@bibr25-1536012120927609]^ Within the xanthene-based PETs, \[^11^C\]TMSX has been successfully evaluated in vivo in rodent (mice and rat) and in nonhuman primate (monkeys) and has detected A~2A~Rs in the brain with good striatum/cerebellum uptake ratio in the above animal species.^[@bibr25-1536012120927609],[@bibr120-1536012120927609][@bibr121-1536012120927609]-[@bibr122-1536012120927609]^ Another xanthine PET ligand \[^11^C\]KF21213 also displayed good striatal/cerebellum uptake ratio in rodent (10.5 at 60 minutes) but showed a lower signal to noise ratio in nonhuman primate brain.^[@bibr121-1536012120927609],[@bibr123-1536012120927609]^ Among the latter 2 xanthene-derived PET radioligands, \[^11^C\]TMSX has been the most suitable radiotracer for mapping the A~2A~Rs and exhibited the highest binding potential in the striatum.^[@bibr120-1536012120927609]^ Currently, \[^11^C\]TMSX is the most broadly used PET imaging radioligand for visualization of A~2A~ receptor in the brain and therefore is considered the gold standard for brain imaging of the A~2A~ receptors.^[@bibr121-1536012120927609],[@bibr122-1536012120927609]^ A major consideration when using this tracer is the fact that dosing and blood sampling need to be performed under dimmed light due to \[^11^C\]TMSX photoisomerization.

![Structures of the adenosine A~2A~ receptor \[^11^C\] PET radioligands: \[^11^C\]TMSX, \[^11^C\]KF21213, \[^11^C\]SCH442416, and \[^11^C\]Preladenant. PET indicates positron emission tomography.](10.1177_1536012120927609-fig4){#fig4-1536012120927609}

To overcome the photoisomerization issue inherent with xanthene radiotracer \[^11^C\]TMSX, a potent, selective, and reversible nonxanthene A~2A~R antagonist SCH442416 was radiolabeled to produce \[^11^C\]SCH442416 and exhibited a good striatum/cerebellum uptake ratio with slow rate of metabolism in rat.^[@bibr124-1536012120927609]^ In rhesus monkeys, \[^11^C\]SCH442416 was rapidly accumulated in the brain, with twice as much radioactivity concentration in the striatum than in the cerebellum, but it showed a high nonspecific binding activity in monkey brain.^[@bibr124-1536012120927609]^ \[^11^C\]SCH442416 has been used to study receptor occupancy and involvement of striatal A~2A~Rs in the brain of PD patients with dyskinesia.^[@bibr125-1536012120927609],[@bibr126-1536012120927609]^ Both A~2A~Rs antagonists \[^11^C\]TMSX and \[^11^C\]SCH442416 have already been used in multiple studies in human.^[@bibr122-1536012120927609],[@bibr124-1536012120927609]^ Preladenant, a PD drug, was also radiolabeled with ^11^C to produce \[^11^C\]Preladenant.^[@bibr126-1536012120927609][@bibr127-1536012120927609]-[@bibr128-1536012120927609]^ Studies of this PET tracer in the brain of monkey showed an uptake that is consistent with the distribution of A~2A~Rs with highest uptake in the putamen and the caudate, respectively.^[@bibr128-1536012120927609]^ The lowest uptake of \[^11^C\]Preladenant was observed in the cerebellum. Estimated binding potential values of \[^11^C\]Preladenant with different scan durations were similar (4.3-5.3 in A~2A~R-rich regions).^[@bibr128-1536012120927609]^ Preinjection with nonradiolabeled Preladenant reduced the tracer uptake in regions rich in A~2A~R and pretreatment with caffeine reduced tracer uptake in the striatum in a dose-dependent manner. \[^11^C\]Preladenant PET is a suitable tool to study A~2A~R occupancy in the brain.^[@bibr128-1536012120927609]^ The regional distribution of \[^11^C\]Preladenant PET is consistent with known A~2A~R densities in the brain.^[@bibr126-1536012120927609]^

### \[^18^F\] PET radio ligands of adenosine A~2A~R {#section8-1536012120927609}

Few ^18^F PET radioligand derivatives of potent and selective A~2A~R antagonist SCH442416 were developed for imaging of the A~2A~Rs. These PET ligands include \[^18^F\]MRS5425 (\[^18^F\]-FESCH),^[@bibr129-1536012120927609],[@bibr130-1536012120927609]^ \[^18^F\]-FPSCH,^[@bibr130-1536012120927609]^ and \[^18^F\]MNI-444^[@bibr131-1536012120927609]^ as shown in [Figure 5](#fig5-1536012120927609){ref-type="fig"}. The A~2A~R-mediated uptake of \[^18^F\]MRS5425 was higher in the striatum of the 6-OHDA lesion-induced rats compared to that of the normal rats, making \[^18^F\]MRS5425 a suitable PET radiotracer for imaging of PD patients.^[@bibr129-1536012120927609]^

![Structures of the adenosine A~2A~ receptor \[^18^F\] PET radioligands: \[^18^F\]MRS5425 (\[^18^F\]-FESCH), \[^18^F\]-FPSCH, and \[^18^F\]MNI-444. PET indicates positron emission tomography.](10.1177_1536012120927609-fig5){#fig5-1536012120927609}

A fluoropropyl analog \[^18^F\]-FPSCH was also developed and studied for mapping of the A~2A~ receptors expression in rat brain.^[@bibr130-1536012120927609]^ Both \[^18^F\]-FESCH and \[^18^F\]-FPSCH showed similar striatum/cerebellum ratios post injection as well as reversible binding in the brains of rat.^[@bibr130-1536012120927609]^ However, dynamic PET imaging for 60 minutes, under baseline and blocking conditions, demonstrated \[^18^F\]MRS5425 (\[^18^F\]-FESCH) to be the most suitable ^18^F PET radioligand for quantifying A~2A~ receptor expression in rat brain.^[@bibr130-1536012120927609]^

Another highly potent nonxanthene ^18^F PET radioligand analog of SCH442416, \[^18^F\]MNI-444 (K~i~ = 2.8 nM, human recombinant A~2A~Rs) was developed to noninvasively monitor A~2A~ receptor densities and functions in the brain of patients with PD.^[@bibr131-1536012120927609]^ \[^18^F\]MNI-444 radioligand has shown high uptake, rapid kinetics, and high target/nontarget ratios in the brain, consistent with A~2A~ receptor distribution.^[@bibr131-1536012120927609],[@bibr132-1536012120927609]^ Thus far, \[^18^F\]MNI-444 has turned out to be a superior imaging tracer among all the ^18^F PET radioligands for studying and mapping the A~2A~R in the brain.^[@bibr133-1536012120927609]^ A list of all A~2A~ receptor PET radioligands is presented in [Table 2](#table2-1536012120927609){ref-type="table"}.

###### 

Adenosine A~2A~ Receptor PET Ligands for CNS Studies.

![](10.1177_1536012120927609-table2)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Receptor   PET ligand             Affinity (nM)      Status                                                                                                                                                                                                                                                                          References
  ---------- ---------------------- ------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------
  A~2A~R     \[^11^C\]TMSX\         5.9 (K~i~, r)      Used widely and considered a gold standard PET ligand for mapping A~2~R. Has been studied in human subjects and in patients with PD, HD, and MS.                                                                                                                                ^[@bibr25-1536012120927609],[@bibr121-1536012120927609],[@bibr122-1536012120927609]^
             (\[^11^C\]KF18446)                                                                                                                                                                                                                                                                                                        

  A~2A~R     \[^11^C\]KF21213       3.0 (K~i~, r)      Possessed high in vitro selectivity (A~2A~/A~1~ \>3300). Good striatal/cerebellum uptake ratio in rodent, but lower signal to noise ratio in nonhuman primate brain.                                                                                                            ^[@bibr25-1536012120927609],[@bibr123-1536012120927609]^\

  A~2A~R     \[^11^C\]SCH442416     0.048 (K~i~, h)\   Studied in patients with PD who suffer from the levodopa-induced dyskinesia. The first suitable nonxanthine A~2A~R PET ligand.                                                                                                                                                  ^[@bibr25-1536012120927609],[@bibr124-1536012120927609]^\
                                    0.5 (K~i~, r)                                                                                                                                                                                                                                                                                      

  A~2A~R     \[^11^C\]Preladenant   1.1 (K~i~, h)\     Studied in rat, rhesus monkeys, and human with PD. First human study was published in 2017.                                                                                                                                                                                     ^[@bibr25-1536012120927609],[@bibr125-1536012120927609],[@bibr126-1536012120927609],[@bibr128-1536012120927609]^
                                    2.5 (K~i~, r)                                                                                                                                                                                                                                                                                      

  A~2A~R     \[^18^F\]MRS5425\      12.4 (K~i~)        Used for quantifying A~2A~ receptor expression in the rat brain and showed higher concentration in the striatum of the 6-OHDA lesion induced in rats, possibly a suitable PET radiotracer for imaging of PD.                                                                    ^[@bibr129-1536012120927609],[@bibr130-1536012120927609]^\
             (\[^18^F\]-FESCH)                                                                                                                                                                                                                                                                                                         

  A~2A~R     \[^18^F\]-FPSCH        53.6 (K~i~)        Propyl analog of \[^18^F\]FESCH and very similar in property, but less suitable PET.                                                                                                                                                                                            ^[@bibr130-1536012120927609]^

  A~2A~R     \[^18^F\]MNI-444       2.8 (K~i~, h)      Exhibited superior property for studying and mapping the A~2A~R in the brain. Used as PET and SPECT radiopharmaceutical to study human brain. Showed high uptake, rapid kinetics, and high target/nontarget ratios in the brain, consistent with A~2A~ receptor distribution.   ^[@bibr25-1536012120927609],[@bibr131-1536012120927609][@bibr132-1536012120927609]-[@bibr133-1536012120927609]^
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: A~2A~R, adenosine 2A receptor; CNS, central nervous system; h, human; HD, Huntington disease; m, mice; MS, multiple sclerosis; 6-OHDA, 6-hydroxydopamine; PD, Parkinson disease; PET, positron emission tomography; r, rat.

P2X Receptors and Functions in the CNS {#section9-1536012120927609}
======================================

P2X receptors (P2XRs) are a family of 7 fast-acting subreceptors P2X~1~ to P2X~7.~ These nonselective cation-gated channels receptors exhibit high Ca^2+^ permeability upon activation by extracellular ATP.^[@bibr134-1536012120927609],[@bibr135-1536012120927609]^. P2X receptors are widely distributed on non-neuronal and neuronal cells and participate in numerous physiological as well as pathophysiological processes.^[@bibr15-1536012120927609]^ Several studies have suggested the change in P2XRs expression under neuroinflammatory, nerve transmission, and pain sensation conditions.^[@bibr136-1536012120927609]^ Activation of some P2XRs has been associated with various pathological disorders of CNS including neuroinflammation and neurodegeneration.^[@bibr36-1536012120927609]^

With the exception of P2X~7~R that is only activated by high concentration of ATP (hundreds of μM), other P2X receptor subtypes are usually activated at high nM to low μM ATP concentration.^[@bibr10-1536012120927609],[@bibr11-1536012120927609]^. In the CNS, P2XRs participate in modulation of neurotransmission, neuron-glia communication, inflammation, and apoptosis.^[@bibr136-1536012120927609][@bibr137-1536012120927609][@bibr138-1536012120927609]-[@bibr139-1536012120927609]^ Adenosine 5′-triphosphate released under physiological conditions modulate synaptic plasticity by acting on P2X receptors via Ca^2+^-dependent interaction with the NMDA receptors that facilitate LTP in the hippocampus.^[@bibr140-1536012120927609]^ In general, overexpression of the P2X~3~, P2X~4~, and P2X~7~ receptors have been detected in CNS disorders and their antagonists could potentially be useful therapies for the treatment of CNS diseases including neurodegeneration and brain injuries.^[@bibr6-1536012120927609],[@bibr136-1536012120927609],[@bibr141-1536012120927609]^ Among subtypes of the P2XRs, P2X~7~R has been the focus of many studies as a therapeutic target for treating brain disorders.^[@bibr142-1536012120927609]^ Herein, we focus on 3, P2X~3~, P2X~4~ and P2X~7~, receptors and review their existing PET radioligands.

P2X~3~ Receptor and Functions in the CNS {#section10-1536012120927609}
----------------------------------------

P2X~3~ receptors, either as a homomeric P2X~3~ or a combination of P2X~2~-P2X~3~ receptors, are primarily expressed on nociceptive sensory neurons^[@bibr143-1536012120927609]^ and mediate the ATP nociceptive signaling.^[@bibr144-1536012120927609]^ In the spinal cord, released ATP from injured cells facilitates glutamate release from primary afferent neurons by its action at the presynaptic P2X~3~ receptors.^[@bibr144-1536012120927609],[@bibr145-1536012120927609]^ P2X~3~ knockout animals have shown to exhibit a reduction of activity of afferent nerves and nociceptive signaling,^[@bibr146-1536012120927609]^ and P2X~3~ receptor expression downregulation by antagonist A-317491 has resulted in reduced mechanical hyperalgesia and neuropathic pain,^[@bibr147-1536012120927609],[@bibr148-1536012120927609]^ supporting the effect of ATP on peripheral nerve afferents.^[@bibr146-1536012120927609]^

Thus far, few antagonists of P2X~3~ and P2X~2/3~ have been identified. One of them, A-317491, has shown to reduce mechanical allodynia and thermal hyperalgesia following chronic nerve constriction.^[@bibr149-1536012120927609],[@bibr150-1536012120927609]^ AF-353 is another P2X~3~ receptor antagonist that has shown similar potency for human and rat recombinant P2X~3~ homotrimers (IC~50~ = 8.7 and IC~50~ = 8.9 nM, respectively).^[@bibr151-1536012120927609]^ A prodrug version of AF-353, (RO-51), has been developed to treat urological dysfunction and chronic pain.^[@bibr152-1536012120927609]^ A recently marketed P2X~3~R antagonist, gefapixant (AF-219, MK-7264), is used for reduction of exaggerated, persistent, and frequent urge to cough as a result of hypersensitized sensory neurons, triggered by injury or infection.^[@bibr153-1536012120927609][@bibr154-1536012120927609]-[@bibr155-1536012120927609]^ Recently, a series of 5-hydroxy pyridine derivatives were synthesized and evaluated for their activities at hP2X~3~ receptors.^[@bibr156-1536012120927609]^ One of the compounds in this series, prodrug 28, has shown antiallodynic activity in spinal nerve ligation and chemotherapy-induced peripheral neuropathy in rats.^[@bibr156-1536012120927609]^ This and other data on the P2X~3~R antagonists indicate that targeting the P2X~3~ receptors could be a promising treatment for neuropathic pain. Thus far, there is no identified PET radioligand for evaluation of the P2X~3~ receptors, to the best of our knowledge.

P2X~4~ Receptor and Functions in the CNS: {#section11-1536012120927609}
-----------------------------------------

P2X~4~ receptor, the first identified P2X receptor, is widely expressed in peripheral nervous system and CNS.^[@bibr157-1536012120927609]^ P2X~4~ receptors are one of the most abundantly expressed functional purinergic receptors found on glial cells and most neurons^[@bibr17-1536012120927609],[@bibr158-1536012120927609]^ and are upregulated on activated microglia after brain and spinal cord injuries.^[@bibr159-1536012120927609]^ Similar to P2X~7~R, P2X~4~R facilitate ion efflux through cell membrane and induces activation of inflammasomes.^[@bibr137-1536012120927609]^ Supporting evidences indicate that P2X4 receptors physically couple with GABA~A~ receptors as well as with the P2X~2~ receptors and this cross talk may play a role in regulating synaptic signaling and plasticity of neurons.^[@bibr160-1536012120927609]^ Alcohol abuse is known to enhance neuroinflammation through P2X~4~Rs activation^[@bibr161-1536012120927609]^ and there are suggestions of implication of P2X~4~Rs in tolerance to morphine and hyperalgesia induction by morphine.^[@bibr161-1536012120927609],[@bibr162-1536012120927609]^ P2X~4~ receptors are upregulated in TBI^[@bibr6-1536012120927609]^, in acute experimental encephalomyelitis (EAE) rodent model of multiple sclerosis^[@bibr17-1536012120927609]^ and following hypoxia and ischemia events.^[@bibr163-1536012120927609]^ In neurons, P2X~4~R has shown to stimulate activation of the inflammasome caspase-1 resulting in cytokines IL-18 and IL-β release, and in P2X~4~R knockout mice, impaired inflammasome signaling was reported to couple to the reduction of IL-β level.^[@bibr164-1536012120927609]^ Inhibition of P2X~4~ receptors by antagonists prior to cerebral ischemia has resulted in an attenuation of the neuroinflammation response and health of neuronal tissue.^[@bibr165-1536012120927609]^ Additionally, P2X4 receptor upregulation has been reported in several rodent models including mechanical allodynia,^[@bibr14-1536012120927609]^ superoxide dismutase 1-mutation models of ALS,^[@bibr166-1536012120927609]^ EAE model of multiple sclerosis,^[@bibr17-1536012120927609]^ post spinal cord injury,^[@bibr164-1536012120927609]^ formalin-induced inflammatory pain,^[@bibr167-1536012120927609]^ TBI,^[@bibr168-1536012120927609]^ and ischemia.^[@bibr165-1536012120927609]^ These data support the central role that P2X4 receptors play in coordinating the microglial response to cellular injuries and/or diseases.

Therefore, P2X~4~ receptor antagonists might have potentials for the treatment of neuropathic pain,^[@bibr23-1536012120927609]^ epilepsy, stroke, multiple sclerosis, and neurodegenerative diseases such as PD and AD.^[@bibr159-1536012120927609],[@bibr169-1536012120927609]^ Paroxetine, a selective serotonin reuptake inhibitor, has shown to behave as an allosteric antagonist of P2X~4~Rs at high concentrations (IC~50~ = 2.45 μM, rat, and IC~50~ = 1.87 μM, human).^[@bibr170-1536012120927609]^ Thus far, attempts to identify potent and selective antagonist of P2X~4~Rs have resulted in the discovery of allosteric ligands with low potency and poor aqueous solubility. Among these antagonists is the benzodiazepine derivative 5-BDBD (IC~50~ = 0.5 μM)^[@bibr171-1536012120927609]^ and its analogs^[@bibr172-1536012120927609]^ that possessed allosteric antagonism, but low potency at P2X~4~R.^[@bibr172-1536012120927609]^ The urea derivative BX-430 was another allosteric P2X~4~ receptor antagonist with low potency (IC~50~ = 0.54 μM).^[@bibr173-1536012120927609]^ An additional allosteric P2X~4~Rs antagonist is the high lipophilic and poor soluble carbamate PSB-12054 with good selectivity and reasonable potency at human P2X~4~Rs but much less potency at rat and mice P2X~4~Rs.^[@bibr174-1536012120927609]^ An analog of PSB-12054, PSB-12062 with better solubility, was developed later and showed equal potency at human, rat, and mouse and good selectivity for P2X~4~R versus P2X~1~, P2X~3~, and P2X~7~ receptors.^[@bibr175-1536012120927609]^ Recently, a new diazepine antagonist NP-1815-PX with reasonable potency and selectivity at P2X~4~Rs (IC~50~ = 0.26 μM, hP2X~4~R, concentration dependent)^[@bibr176-1536012120927609]^ has shown an antiallodynic effect and suppression of mechanical allodynia in mice with traumatic nerve damage without affecting acute nociceptive pain and motor function, suggesting that microglial P2X~4~Rs could potentially act as an important target for treating chronic pain.^[@bibr176-1536012120927609]^ Nippon Chemiphar has reported the discovery of yet another potent antagonist of the P2X~4~Rs, NC-2600 for the treatment of neuropathic pain. Phase I evaluation of NC-2600 has been completed and phase II evaluation is underway. NC-2600 is believed to be the first-in-class candidate to control pain by targeting glial cells. NC-2600 is currently under safety/tolerability studies. To our best knowledge, lack of highly potent P2X~4~Rs ligands has limited efforts to develop PET ligand for this receptor.

P2X~7~ Receptor and Functions in the CNS {#section12-1536012120927609}
----------------------------------------

P2X~7~R is regarded as an important silent receptor as its expression is only upregulated when ATP concentration increases to a high level,^[@bibr177-1536012120927609]^ suggesting the high relevance of P2X~7~Rs in pathological conditions.^[@bibr178-1536012120927609]^ P2X~7~Rs are expressed on presynaptic neurons, astrocytes, and oligodendrocytes, but its highest concentrations is expressed on microglia where it releases pro-inflammatory cytokine IL-1β, a key mediator of chronic inflammation and chronic pain.^[@bibr6-1536012120927609],[@bibr178-1536012120927609]^ Several studies of the P2X~7~ receptors have shown involvement of this receptor in animal models of neuroinflammatory diseases including AD,^[@bibr137-1536012120927609],[@bibr179-1536012120927609],[@bibr180-1536012120927609]^ PD,^[@bibr181-1536012120927609]^ HD,^[@bibr182-1536012120927609]^ FD,^[@bibr1-1536012120927609]^ ALS,^[@bibr183-1536012120927609]^ MS,^[@bibr184-1536012120927609]^ TBI,^[@bibr15-1536012120927609]^ cerebral ischemia,^[@bibr6-1536012120927609]^ epilepsy,^[@bibr185-1536012120927609]^ depression,^[@bibr186-1536012120927609],[@bibr187-1536012120927609]^ anxiety, and bipolar disorders.^[@bibr178-1536012120927609]^ Astrocytic P2X~7~Rs expression has also shown to be involved in the neurotoxic phenotype model of ALS.^[@bibr188-1536012120927609]^

Stimulation of P2X~7~Rs by high level of ATP (hundreds of μM) produces a large transmembrane pores, permeable to large molecular sizes of up to 900 Da, promoting further increase in extracellular ATP release that can lead to activation of caspases and result in cell death.^[@bibr189-1536012120927609]^ P2X~7~ receptor expression in the CNS could be increased with systemic administration of bacterial lipopolysaccharide (LPS), providing a realistic mechanism similar to systemic infection in the brain.^[@bibr6-1536012120927609]^ Genetic deficiency and pharmacological inhibition of P2X~7~ receptors have shown to attenuate hyperactivity induced by amphetamine in the model of manic bipolar disorder.^[@bibr190-1536012120927609]^ Mood stabilizer drugs such as lithium and valproate reversed ATP-induced cell death in the hippocampus, an action that is probably mediated by P2X~7~ receptors.^[@bibr191-1536012120927609],[@bibr192-1536012120927609]^

Discovery of a number of potent and selective P2X~7~Rs antagonists has been instrumental in studying the receptor in human and rodent. Some of these ligands including AZD9056^[@bibr193-1536012120927609]^ and CE-224535^[@bibr194-1536012120927609]^ were developed for the treatment of inflammation but failed to exhibit benefits in patients.^[@bibr194-1536012120927609]^ Other existing and understudy ligands of the P2X~7~ receptors include A438079, A740003, A804598, A839977, AZ1060612, AZ11645373, GSK1482160, and GW791343.^[@bibr9-1536012120927609],[@bibr195-1536012120927609]^

Some P2X~7~ receptor antagonists were specifically developed to study disorders of the CNS. These are the brain penetrant benzamides GSK1482160,^[@bibr196-1536012120927609]^ JNJ-42253432,^[@bibr197-1536012120927609]^ JNJ-47965567,^[@bibr198-1536012120927609]^ triazoles JNJ-54232334 and JNJ-54140515,^[@bibr199-1536012120927609]^ JNJ-54166060,^[@bibr200-1536012120927609]^ JNJ-54173717,^[@bibr201-1536012120927609]^ JNJ-54175446,^[@bibr202-1536012120927609]^ and JNJ-55308942.^[@bibr203-1536012120927609]^ These molecules have demonstrated P2X~7~ receptor antagonist activities in rodent and human. Three of these molecules, GSK1482160, JNJ-54175446, and JNJ-55308942, have already moved into clinical trials for evaluation of the disorders of CNS.^[@bibr187-1536012120927609]^

Association of P2X~7~R activation with pro-inflammatory phenotype of microglia in CNS diseases makes P2X~7~R an interesting and valuable biomarker of inflammation.^[@bibr9-1536012120927609]^ Development of useful PET radioligands for imaging the P2X~7~Rs in CNS can potentially enable studies of the pharmacology and functional role of this receptor in neuroinflammation and evaluate the effect of therapeutic agents in treating neuroinflammatory and neurodegenerative diseases. Fortunately, an ample number of potent and selective P2X~7~R ligands has presented opportunities to develop a few ^11^C and ^18^F PET radioligands of the receptor as described herein.^[@bibr24-1536012120927609],[@bibr204-1536012120927609]^

### \[^11^C\] PET radioligands of P2X~7~R {#section13-1536012120927609}

Several antagonists of the P2X~7~R have been radiolabeled with ^11^C for evaluation of the receptor expression and function as shown in [Figure 6](#fig6-1536012120927609){ref-type="fig"}. The selective P2X~7~R antagonist A-740003 (IC~50~ = 18 nM, rP2X7R and IC~50~ = 40 nM, hP2X7R) was radiolabeled with ^11^C to produce \[^11^C\]A-740003,^[@bibr205-1536012120927609]^ but showed low biodistribution and poor brain permeability.^[@bibr205-1536012120927609]^ The first brain penetrable ^11^C PET radioligand for quantification of P2X~7~R expression in the brain was \[^11^C\]JNJ-54173717. This tracer showed high potency in humanized rat P2X~7~R (IC~50~ = 4.2 nM, hP2X7R)^[@bibr206-1536012120927609]^ and excellent uptake in the hP2X~7~R overexpressing striatum area that was reduced by pretreatment with nonradioactive antagonists JNJ-54173717 and JNJ-42253432, suggesting selective P2X~7~R binding of this radiotracer in the brain.^[@bibr24-1536012120927609]^ Additionally, \[^11^C\]JNJ-54173717 displayed high brain uptake in rhesus monkey, an indication of BBB penetrability to study receptor expression levels in neurodegenerative disorders in humans.^[@bibr206-1536012120927609]^ Another potent P2X~7~ receptor antagonist, benzamide GSK1482160 was also radiolabeled with ^11^C to produce PET radioligand \[^11^C\]GSK1482160 (Ki = 2.63 nM, IC~50~ = 3 nM, hP2X~7~ and K~d~ = 1.15 ± 0.12 nM, hP2X7R).^[@bibr207-1536012120927609][@bibr208-1536012120927609]-[@bibr209-1536012120927609]^ Evaluation of \[^11^C\]GSK1482160 in mouse model of LPS-induced neuroinflammation showed increased uptake of 3.6-fold compared with saline-treated mice in all studied organs (2.9- to 5.7-fold).^[@bibr208-1536012120927609]^ In the EAE rat model of MS, \[^11^C\]GSK1482160 uptake was high in rat lumbar spinal cord and the highest uptake was measured at the EAE peak stage.^[@bibr209-1536012120927609]^ Micro-PET studies of \[^11^C\]GSK1482160 in rhesus monkey has shown high tracer retention and a homogeneous brain distribution.^[@bibr209-1536012120927609]^ All of these studies strongly correlated the \[^11^C\]GSK1482160 uptake with the P2X~7~ R overexpression on activated microglia and its participation in neuroinflammation.^[@bibr209-1536012120927609]^ Another ^11^C PET radioligand of P2X~7~ R antagonist was developed by radiolabeling of the SMW139 (K~i~ = 32 nM, hP2X~7~R)^[@bibr210-1536012120927609]^ and was evaluated in a humanized rat model to study the expression of P2X~7~R in striatum.^[@bibr210-1536012120927609]^ Even though \[^11^C\]SMW139 did not detect overexpression of the P2X~7~ R in postmortem brain of patients with AD,^[@bibr210-1536012120927609],[@bibr211-1536012120927609]^ this PET radioligand has entered clinical evaluation in patients with MS and is currently the first in human to study neuroinflammation in patients with MS.^[@bibr210-1536012120927609],[@bibr212-1536012120927609]^

![Structures of the P2X~7~ receptor \[^11^C\] PET radioligands: \[^11^C\]A-740003, \[^11^C\]JNJ-54173717, \[^11^C\]GSK1482160, and \[^11^C\]SMW139. PET indicates positron emission tomography.](10.1177_1536012120927609-fig6){#fig6-1536012120927609}

### \[^18^F\] PET radioligands of P2X~7~R {#section14-1536012120927609}

Thus far, there are reports of 3 known ^18^F radioligands for evaluation of the P2X~7~R expression as shown in [Figure 7](#fig7-1536012120927609){ref-type="fig"}. An analog of a potent P2X~7~R antagonist A-804598 was radiolabeled with ^18^F to yield \[^18^F\]EFB that showed high affinity for human and rat P2X~7~R.^[@bibr213-1536012120927609]^ However, this PET tracer suffered from a low brain uptake in both healthy and LPS-treated rats that limited its application for brain imaging of the receptor.^[@bibr213-1536012120927609]^ Another PET radioligand \[^18^F\]JNJ-64413739 was developed by ^18^F radiolabeling of a potent and selective P2X~7~ R antagonist JNJ-64413739 (Ki = 2.7 nM, rat cortex, Ki = 15.9 nM, hP2X7R). \[^18^F\]JNJ-64413739 has shown to be an effective PET ligand for mapping of P2X~7~R in human brain.^[@bibr214-1536012120927609]^ The PET imaging studies with \[^18^F\]JNJ-64413739 in nonhuman primate showed engagement of the tracer with the P2X~7~R. In vitro blocking experiments of \[^18^F\]JNJ-64413739 with 2 known P2X~7~R antagonists demonstrated inhibition of the tracer binding to rat brain tissue sections in a dose-dependent manner.^[@bibr214-1536012120927609][@bibr215-1536012120927609]-[@bibr216-1536012120927609]^ While \[^18^F\]JNJ-64413739 may be a useful tool for imaging of neuroinflammation, lack of a reference region in image analysis (ie, similar to TSPO) might hinder its use as an optimum PET radiotracer for detection of neuroinflammation.^[@bibr214-1536012120927609],[@bibr217-1536012120927609]^ Most recently, our team has synthesized a novel ^18^F radioligand \[^18^F\]IUR-1601, the fluoroethyl analog of GSK1482160.^[@bibr218-1536012120927609]^ \[^18^F\]IUR-1601 has been successfully evaluated in vitro and is currently under evaluation in 5XFAD animal model of AD. A list of all P2X~7~ receptor PET radioligands is presented in [Table 3](#table3-1536012120927609){ref-type="table"}.

![Structures of the P2X~7~ receptor \[^18^F\] PET radioligands: \[^18^F\]EFB, \[^18^F\]JNJ-64413739, and \[^18^F\]IUR-1601. PET indicates positron emission tomography.](10.1177_1536012120927609-fig7){#fig7-1536012120927609}

###### 

P2X~7~ Receptor PET Ligands for CNS Studies.

![](10.1177_1536012120927609-table3)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Receptor   PET ligand              Affinity (nM)             Status                                                                                                                                                                                                                                                                          References
  ---------- ----------------------- ------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------
  P2X~7~R    \[11C\]A-740003         18 (IC~50~, r)\           Showed low brain uptake and a moderate metabolic rate.                                                                                                                                                                                                                          ^[@bibr205-1536012120927609]^
                                     40 (IC~50~, h)                                                                                                                                                                                                                                                                                            

  P2X~7~R    \[^11^C\]JNJ-54173717   1.6 ± 0.1 (K~i~, r)\      Entered rat brain and showed excellent uptake in the human P2X7R overexpressing striatum. Showed high initial brain uptake in nonhuman primates.                                                                                                                                ^[@bibr201-1536012120927609],[@bibr206-1536012120927609]^
                                     4.2 (IC~50~, h)\                                                                                                                                                                                                                                                                                          
                                     7.6 (IC~50~, r)                                                                                                                                                                                                                                                                                           

  P2X~7~R    \[^11^C\]GSK1482160     2.63 ± 0.6 (K~i~)\        Possessed high P2X7 selectivity and good blood--brain barrier permeability. Studied in mouse model of LPS-induced neuroinflammation and EAE rat model of MS. Showed a high tracer retention and a homogeneous brain distribution in rhesus monkey. In preclinical evaluation.   ^[@bibr196-1536012120927609],[@bibr207-1536012120927609][@bibr208-1536012120927609]-[@bibr209-1536012120927609]^
                                     1.15 ± 0.12 (K~d~)\                                                                                                                                                                                                                                                                                       
                                     3 (IC~50~, h)                                                                                                                                                                                                                                                                                             

  P2X~7~R    \[^11^C\]SMW139         32 ± 5 (K~i~, h)\         Entered clinical trial to study neuroinflammation in patients with MS.                                                                                                                                                                                                          ^[@bibr210-1536012120927609][@bibr211-1536012120927609]-[@bibr212-1536012120927609]^
                                     24.5 ± 5.5 (IC~50~, h)\                                                                                                                                                                                                                                                                                   
                                     158 ± 44 (IC~50~, m)                                                                                                                                                                                                                                                                                      

  P2X~7~R    \[^18^F\]EFB\           2.88 (K~i~, h)\           Exhibited low brain uptake due to limited compatibility of the cyanoguanidine moiety with BBB entry in rats. Limited solubility.                                                                                                                                                ^[@bibr213-1536012120927609]^
                                     36.1 (K~i~, r)\                                                                                                                                                                                                                                                                                           
                                     547 (K~i~, m)                                                                                                                                                                                                                                                                                             

  P2X~7~R    \[^18^F\]JNJ-64413739   15.9 ± 2.0 (K~i~, h)\     Showed dose-dependent competitive binding with JNJ-54175446 in monkey PET studies. A potential imaging biomarker of central neuroinflammation. Entered clinical trial in 2017.                                                                                                  ^[@bibr214-1536012120927609][@bibr215-1536012120927609][@bibr216-1536012120927609]-[@bibr217-1536012120927609]^\
                                     2.7 ± 1.1 (K~i~, r)\                                                                                                                                                                                                                                                                                      
                                     1.0 ± 0.2 (IC~50~, h)\                                                                                                                                                                                                                                                                                    
                                     2.0 ± 0.6 (IC~50~, r)                                                                                                                                                                                                                                                                                     

  P2X~7~R    \[^18^F\]IUR-1601       4.31 (K~i~)\              Evaluated in *in vitro* assays and is currently under evaluation in 5XFAD animal model of AD.                                                                                                                                                                                   ^[@bibr218-1536012120927609]^\
                                     7.86 (IC~50~)                                                                                                                                                                                                                                                                                             
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AD, Alzheimer disease; BBB, brain--blood barrier; CNS, central nervous system; h, human; LPS, lipopolysaccharides; m, mice; MS, multiple sclerosis; PET, positron emission tomography; P2X~7~R, P2X~7~ receptor; r, rat.

P2Y Receptors and Functions in the CNS {#section15-1536012120927609}
======================================

The metabotropic P2Y receptors are a family of GPCRs with 8 subtypes: P2Y~1~, P2Y~2~, P2Y~4~, P2Y~6~, P2Y~11~, P2Y~12~, P2Y~13~, and P2Y~14~, with ubiquitous expression and effect in body.^[@bibr18-1536012120927609],[@bibr219-1536012120927609]^ In the CNS, P2Y receptors are localized on neurons, microglia, astrocytes, and oligodendrocytes where they have important physiological roles in glial-cell communication, neurotransmission, and neurogenesis.^[@bibr220-1536012120927609],[@bibr221-1536012120927609]^ The hippocampus expresses P2Y~1~, P2Y~2~, P2Y~4~, P2Y~6~, and P2Y~12~ receptors in addition to all the P2X receptor subtypes.^[@bibr67-1536012120927609]^

In contrast to the ion channel P2X receptors, P2YRs are activated by several endogenous ligands including the adenine nucleotides: ADP (acting on P2Y~1~, P2Y~12~, and P2Y~13~) and ATP (acting on P2Y~2~ and P2Y~11~), and the uridine nucleotides UTP (acting on P2Y~2~ and P2Y~4~), UDP (acting on P2Y~6~), and the UDP-glucose (acting on P2Y~14~).^[@bibr222-1536012120927609]^

Several studies have revealed that during brain injury and under pathological conditions, neurons,^[@bibr223-1536012120927609]^ astrocytes,^[@bibr189-1536012120927609]^ and microglia^[@bibr224-1536012120927609]^ release high concentration of ATP that acts as a neuromodulator of the P2Y receptors.^[@bibr134-1536012120927609],[@bibr225-1536012120927609]^ P2Y receptor activation then induces fast synaptic transmission through postsynaptic P2X receptors in the brain.^[@bibr135-1536012120927609]^ Therefore, P2Y receptors affect the release of number of neurotransmitters^[@bibr225-1536012120927609]^ through actions on calcium influx.^[@bibr226-1536012120927609]^

The P2Y receptors, individually or in combination, participate in many biological conditions. P2Y~1~R has a complex role in modulation of DA release, even though there is no evidence of its existence in the dopaminergic terminals of the prefrontal cortex.^[@bibr227-1536012120927609],[@bibr228-1536012120927609]^ P2Y~1~, P2Y~12~, and P2Y~13~ receptors specifically block the release of noradrenaline in the spinal cord,^[@bibr229-1536012120927609]^ the hippocampus,^[@bibr230-1536012120927609]^ and in the cortex,^[@bibr228-1536012120927609]^ while these same receptors inhibit the release of serotonin in the cortex.^[@bibr231-1536012120927609]^ P2Y~1~, P2Y~2~, P2Y~4~, P2Y~12~, and P2Y~13~ receptors have also shown to inhibit the release of glutamate in the spinal cord,^[@bibr226-1536012120927609]^ the hippocampus synapses, and the cerebral cortex.^[@bibr221-1536012120927609]^ P2Y~12~ receptor is known as a protective receptor that stimulates microglial migration toward neuronal damage.^[@bibr16-1536012120927609]^ Functional studies have demonstrated the involvement of P2Y receptors in seizure pathology, as well.^[@bibr232-1536012120927609]^

Some of the P2Y receptors have prominent roles in neurodegenerative diseases. For example, during neuronal injuries, P2Y~2~, P2Y~4~, and P2Y~6~ receptors regulate the phagocytic activity of microglia upon leaked UTP and UDP from injured hippocampal cells.^[@bibr233-1536012120927609]^ Microglia execute the uptake of cellular debris specifically through P2Y~6~ receptor.^[@bibr233-1536012120927609]^ P2Y~1~, P2Y~4~, and P2Y~12~ are prominent P2YRs in the brain and represent favorable targets for treating neuroinflammatory diseases and neurodegenerative disorders including AD.^[@bibr46-1536012120927609],[@bibr226-1536012120927609]^

Activation of some P2YRs has shown to inhibit the excitatory transmission mediated by postsynaptic NMDA receptors and increase the inhibitory action of the GABA~A~ receptors prompting LTP.^[@bibr226-1536012120927609],[@bibr234-1536012120927609]^ In the CA1 region of hippocampus, released ATP from astrocytes has shown to result in LTD of synapses from neighboring neurons via activation of the presynaptic P2Y receptors, indicating participation of ATP from activated astrocytes in this form of plasticity.^[@bibr140-1536012120927609]^ In a specific region of the brain, the medial habenular nucleus that is involved in depression, stress, and nicotine withdrawal^[@bibr234-1536012120927609],[@bibr235-1536012120927609]^ an application of UTP or UDP resulted in LTP of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor-mediated currents, apparently through activation of presynaptic P2Y~4~R.^[@bibr226-1536012120927609]^

There has been suggestions that activation of P2Y~2~ and P2Y~4~ receptors may be useful in treating neurodegenerative diseases.^[@bibr18-1536012120927609],[@bibr221-1536012120927609]^ Studies of rat primary cerebellar neurons has provided evidence that P2Y~13~ receptor activation protected neurons against oxidative stress-induced death.^[@bibr236-1536012120927609]^ P2Y~1~ receptor has specifically emerged as a new target for treating cognitive dysfunction in CNS.^[@bibr226-1536012120927609],[@bibr237-1536012120927609],[@bibr238-1536012120927609]^

Overall, investigations of the P2Y family receptors have been challenging due to the lack of potent, selective, and high-specific-radioactivity PET radioligands for these receptors. Herein, we present the subfamily of P2Y receptors and their ligands that are known to have important functions in the CNS.

P2Y~1~ Receptor and Functions in the CNS {#section16-1536012120927609}
----------------------------------------

P2Y~1~ receptor is one of the most abundant P2Y receptor subtype in brain tissues with large expression on neurons of the cerebellum,^[@bibr237-1536012120927609]^ cerebral cortex, and ischemia-sensitive regions of the hippocampus that is predominantly implicated in AD.^[@bibr239-1536012120927609]^ P2Y~1~R is also expressed on oligodendrocytes and astrocytes in the brain and optic nerves.^[@bibr240-1536012120927609],[@bibr241-1536012120927609]^ Human P2Y~1~R is activated by ADP (EC~50~ = 10 nM),^[@bibr220-1536012120927609],[@bibr221-1536012120927609]^ and ADP activation of the receptor induces platelet activation making this receptor as an important antithrombotic drug target.^[@bibr242-1536012120927609]^ Like P2X~7~ receptor, P2Y~1~ receptor also mediates activation of microglia after brain injuries and insult.^[@bibr243-1536012120927609]^

There are reports of P2Y~1~ receptor upregulation in CNS under pathological conditions such as mechanical injury,^[@bibr244-1536012120927609]^ ischemia,^[@bibr245-1536012120927609]^ and neurodegeneration.^[@bibr246-1536012120927609]^ Additionally, hyperactivity of astrocytic P2Y~1~ receptors have been detected in animal models of AD^[@bibr246-1536012120927609],[@bibr247-1536012120927609]^ and increased expression of the receptor has been observed in hippocampus and cortex of postmortem brain sections in patients with AD.^[@bibr248-1536012120927609]^ P2Y~1~R is also upregulated after stroke and TBI and inhibition of the receptor has been shown to reduce cognition deficit resulted from these conditions.^[@bibr249-1536012120927609]^ Indeed, antagonists of the P2Y~1~ receptor have shown to reduce neuronal injury and improve spatial memory in rat model of TBI.^[@bibr250-1536012120927609],[@bibr251-1536012120927609]^

Inhibition of astrocytic P2Y~1~R has resulted in cytokine and chemokine transcriptional suppression and brain protection.^[@bibr247-1536012120927609],[@bibr250-1536012120927609]^ Blocking of hippocampal P2Y~1~ receptors has shown to enhance synaptic signaling and might be responsible for promotion of antioxidant mechanism that consequently results in pro-survival pathways.^[@bibr249-1536012120927609],[@bibr252-1536012120927609]^ P2Y~1~R antagonists have also shown to mediate and upregulate the oxidoreductase enzymes by increasing tolerance to hydrogen peroxide.^[@bibr253-1536012120927609]^ A recent study has shown that P2Y~1~ agonist MRS2365 initiated nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) release after stroke and enhanced neuroinflammatory responses, while P2Y~1~ receptor antagonist MRS2179 attenuated inflammation and reduced the infarct size.^[@bibr250-1536012120927609],[@bibr251-1536012120927609]^ Furthermore, P2Y~1~ antagonist has shown to help patients with schizophrenia to experience reduction in unnecessary information and noise entering their brain.^[@bibr254-1536012120927609]^

Ironically, there is an evidence that P2Y~1~Rs may also promote axonal elongation to offset the neurotoxic effects of neurofibrillary tangles and have a neuroprotective effect in patients with AD.^[@bibr255-1536012120927609]^ Nevertheless, there are still more supporting data that P2Y~1~R antagonist could potentially be appropriate candidates for the treatment of neurodegenerative diseases.^[@bibr247-1536012120927609][@bibr248-1536012120927609]-[@bibr249-1536012120927609]^

### PET radioligand of P2Y~1~R {#section17-1536012120927609}

Overall, investigation of the P2Y family receptors has been challenging due to the absence of potent, selective, and high-specific-radioactivity PET radioligands. Recently, a highly potent (IC~50~ = 10 nM) P2Y~1~R antagonist (compound 18) was identified and radiolabeled with \[^18^F\] (\[^18^F\]18) as shown in [Figure 8](#fig8-1536012120927609){ref-type="fig"}. Although \[^18^F\]18 exhibited fast in vivo metabolism, its high potency and unique allosteric binding mode has provided an opportunity to investigate it as a potential PET tracer for mapping the P2Y~1~ receptor.^[@bibr256-1536012120927609]^ Additionally, highly potent, selective, and high specific radioligand \[^32^P\]MRS2500 has been used successfully to measure human P2Y~1~ receptor expression in Sf9 insect cell membrane.^[@bibr257-1536012120927609]^

![\[^18^F\]Radiolabeled P2Y~1~R PET ligand \[^18^F\]18. PET indicates positron emission tomography.](10.1177_1536012120927609-fig8){#fig8-1536012120927609}

P2Y~2~ Receptor and Functions in the CNS {#section18-1536012120927609}
----------------------------------------

One of the most studied receptors in this family is the P2Y~2~R, with a wide distribution in all cells in human body and particularly in immune cells.^[@bibr258-1536012120927609]^ In the brain, P2Y~2~ receptor is expressed on neurons, microglia, and astrocytes.^[@bibr12-1536012120927609],[@bibr259-1536012120927609]^ Under normal brain conditions, there is a low expression of P2Y~2~R on neurons, but it can be upregulated to exert neuroprotective effects against the release of pro-inflammatory cytokine IL-1β as a result of P2X~7~R expression on activated microglia.^[@bibr260-1536012120927609]^ In the AD mouse model TgCRND8, genetic deletion of P2Y~2~ receptor has shown to enhance early AD pathology, while activation of the receptor enhanced phagocytosis and degradation of the Aβ peptide.^[@bibr261-1536012120927609]^ Furthermore, activation of P2Y~2~R has proven to result in degradation of amyloid precursor protein by α-secretase, yielding to soluble APPα peptide that prevented production and accumulation of the neurotoxic Aβ~1-42.~ ^[@bibr262-1536012120927609],[@bibr263-1536012120927609]^ In studies that compared brain neocortex and parietal cortex of postmortem patients with AD to those of the normal aged controls, the low level of P2Y~2~R expression was associated with neuropathology and synapse loss in patients with AD,^[@bibr263-1536012120927609]^ presenting additional support for neuroprotective function of P2Y~2~R in AD pathology.^[@bibr264-1536012120927609]^ Additionally, activation of the P2Y~2~R has shown to promote neurite outgrowth.^[@bibr265-1536012120927609]^ These studies suggest that loss of neuroprotective functions of P2Y~2~R might contribute to disease pathogenesis in AD, and therefore, targeting the P2Y~2~Rs with agonist might be a promising strategy to boost neuroprotection in neurodegenerative diseases.

P2Y~2~R is equally activated by ATP and UTP (EC~50~ = 0.3-3 μM),^[@bibr221-1536012120927609]^ suggesting its close proximity to conditions such as inflammation and apoptosis.^[@bibr258-1536012120927609]^ All known agonists of P2Y~2~R are derivatives of ATP and UDP (UDPpS, MRS2698, INS37217, INS48823, α,β-methylene-UDP, 5-bromo-UTP, PSB-1114). One such agonist INS365 (diquafosol, EC~50~ = 100 nM) has been approved as an ophthalmic solution for the treatment of dry eye syndrome.^[@bibr266-1536012120927609]^ PSB1114 is another known P2Y~2~R agonist that possesses 60-fold selectivity over the P2Y~4~R or the P2Y~6~R.^[@bibr267-1536012120927609]^ Two of the P2Y~2~R agonists INS37217 and MRS2698 are currently in clinical trials for treating cystic fibrosis.^[@bibr258-1536012120927609]^ Thus far, there are no reports of any PET radioligand for imaging of this receptors.

P2Y~4~ Receptor and Functions in the CNS {#section19-1536012120927609}
----------------------------------------

The P2Y~4~R is present in all cells of the brain, including neurons,^[@bibr268-1536012120927609]^ astrocytes,^[@bibr269-1536012120927609]^ and microglia.^[@bibr270-1536012120927609]^ However, the functional role of the receptor is still ambiguous. It is believed that P2Y~4~ R might complement the P2Y~2~R since both receptors are present in glial end feet in vicinity of the blood vessel walls.^[@bibr271-1536012120927609]^ Human P2Y~4~R is stimulated by UTP (EC~50~ = 73 nM), but not by ATP.^[@bibr272-1536012120927609]^ However, both nucleotides activate the rat and mouse P2Y~4~ receptors. In microglia, P2Y~4~ receptors are involved in ATP triggered pinocytosis that results in the uptake of soluble Aβ~1-42~, and either P2Y~4~ knockdown or ATP deficiency has shown to decrease this process.^[@bibr273-1536012120927609]^ Hence, in addition to the P2Y~12~ receptor-mediated "find me" signal^[@bibr16-1536012120927609]^ and the P2Y~6~ receptor-mediated "eat me" signal,^[@bibr233-1536012120927609]^ P2Y~4~ receptors facilitate "drink me" signal that enables uptake of soluble Aβ by microglia.^[@bibr273-1536012120927609]^ Therefore, activation of P2Y~4~ receptor in AD may have a neuroprotective effect possibly through uptake of Aβ~1-42.~ ^[@bibr273-1536012120927609],[@bibr274-1536012120927609]^

Thus far, there has been no report of a selective P2Y~4~R agonists or antagonists. Nonselective P2Y agonists UTPγS,^[@bibr275-1536012120927609]^ 5-bromo-UTP,^[@bibr276-1536012120927609]^ INS365, INS37217, and INS45973 also exhibit agonist activity for the P2Y~4~R.^[@bibr277-1536012120927609],[@bibr278-1536012120927609]^ Recently, an anthraquinone derivative was synthesized and showed selective and noncompetitive antagonist activity at the hP2Y4Rs (IC~50~ = 233 nM).^[@bibr279-1536012120927609]^ To the best of our knowledge, there has been no report of any PET radioligand for mapping of the P2Y~4~Rs thus far.

P2Y~6~ Receptor and Functions in the CNS {#section20-1536012120927609}
----------------------------------------

The P2Y~6~ receptor is distributed on both immune and nonimmune cells and plays an important role in mammalian innate immunity.^[@bibr280-1536012120927609]^ It is preferentially activated by UDP (EC~50~ = 15 nM).^[@bibr221-1536012120927609]^ Under conditions that cause neuronal damage or in response to LPS, UDP leakage from damaged cells facilitates uptake and removal of cellular debris by activation of the microglial P2Y~6~ receptors,^[@bibr6-1536012120927609],[@bibr281-1536012120927609]^ especially in PD.^[@bibr221-1536012120927609]^ Indeed, P2X~6~R is regarded as a potential clinical biomarker of PD and other neuroinflammatory diseases.^[@bibr282-1536012120927609]^

Additionally, UDP has shown to promote feeding through activation of P2Y~6~ receptors in AgRP neurons. These neurons are known to be involved in systemic insulin resistance which is an onset of obesity-associated hyperphagia.^[@bibr283-1536012120927609]^ Moreover, hypothalamic UDP concentrations have shown to be increased in obesity disorder.^[@bibr283-1536012120927609]^

Inhibition of P2Y~6~R has proven to be a potential therapeutic strategy for treatment of neuroinflammation, PD,^[@bibr282-1536012120927609]^ feeding disorders, and systemic insulin resistance in obesity condition.^[@bibr283-1536012120927609]^ Potent and selective nonnucleotide P2Y~6~R antagonist MRS2578 (IC50 = 37 nM, hP2Y~6~ R and IC50 = 98 nM, rP2Y~6~R) has shown to inhibit UDP-induced phagocytosis and prevent LPS-induced neuronal loss in mixed neuronal/glial cultures.^[@bibr284-1536012120927609]^ MRS2578 specifically lacks any antagonist activity at P2Y~1,2,4,11~ receptors.^[@bibr285-1536012120927609],[@bibr286-1536012120927609]^ Recently, a novel selective hP2Y~6~R antagonist TIM-38 was reported with low potency (IC~50~ = 4.3 μM).^[@bibr287-1536012120927609]^ TIM-38 could be a useful pharmacological tool and a starting point for the development of therapeutic agents against P2Y~6~ receptor-implicated disease. Activation of P2Y~6~R by either its endogenous ligand UDP or selective agonist MRS-2693 has shown to promote production of pro-inflammatory cytokines IL-6 and IL-8 and contribute to phagocytosis of neurons.^[@bibr288-1536012120927609],[@bibr289-1536012120927609]^ To the best of our knowledge, there has been no report of any PET radioligand for mapping of the P2Y~6~Rs.

P2Y~12~ Receptor and Functions in the CNS {#section21-1536012120927609}
-----------------------------------------

P2Y~12~ receptor is activated by endogenous agonist ADP (EC~50~ = 60 nM).^[@bibr221-1536012120927609]^ It acts as a regulator of blood clotting; therefore, it is targeted for the treatment of thromboembolisms.^[@bibr290-1536012120927609]^ In normal brain, P2Y~12~R expression level is high on M2 type microglia^[@bibr291-1536012120927609]^ but downregulates under pathological conditions or after LPS treatment.^[@bibr291-1536012120927609],[@bibr292-1536012120927609]^ Indeed, expression of P2Y~12~ in microglia was undetectable 24 hours after injury.^[@bibr16-1536012120927609]^ During microglial transition from highly ramified to an amoeboid state, low level of P2Y~12~ receptors is an indication of the receptor role in early responses of microglia to the brain injury.^[@bibr16-1536012120927609]^ Immunohistochemical studies of postmortem brains from patients with AD and MS have shown reduction of P2Y~12~ receptor expression on microglia near the injury sites.^[@bibr291-1536012120927609]^ Therefore, P2Y~12~ receptor could potentially act as a valuable biomarker for detecting the activity of human microglia during CNS pathologies in neurodegenerative diseases.^[@bibr291-1536012120927609]^ P2Y~12~ is also expressed on astrocytes of the rat cortex and hippocampal pyramidal neurons and on oligodendrocytes where is involved in myelination.^[@bibr271-1536012120927609],[@bibr293-1536012120927609]^

Within the P2Y receptor family, both P2Y~12~ and P2Y~6~ receptors^[@bibr233-1536012120927609]^ control microglia activation and migration to the injury site; however, P2Y~12~R expression is decreased, while P2Y~6~R expression is increased.^[@bibr294-1536012120927609],[@bibr295-1536012120927609]^ P2Y~12~ receptor also participates in a crosstalk with A~3~R to perform the process extension of microglia,^[@bibr296-1536012120927609]^ suggesting the nucleotides action on P2Y~12~ as a primary target to induce microglial chemotaxis early on in response to CNS injury. Therefore, P2Y~12~R can potentially be targeted for the treatment of neurodegenerative diseases.^[@bibr16-1536012120927609]^

A wide variety of antithrombotic P2Y~12~R antagonists such as ticlopidine (Ticlid), clopidogrel (Plavix), ticagrelor (Brilinta), prasugrel (Effient), ticagrelor (AR-C 69931),^[@bibr297-1536012120927609]^ and MRS-2395^[@bibr298-1536012120927609]^ have been developed for the treatment of platelet aggregation.^[@bibr269-1536012120927609],[@bibr299-1536012120927609]^ Inhibition of the P2Y~12~R through knockdown of expression or by pharmacological inhibitor has resulted in less neuronal injury.^[@bibr294-1536012120927609]^ The direct effects of the P2Y~12~ antagonists on cardiovascular system may indirectly heal neural injury and CNS diseases.^[@bibr16-1536012120927609]^ Therefore, inhibition of both P2Y~6~ and P2Y~12~ receptors with their antagonists may prevent phagocytosis of salvageable cells and could be a promising path in treating neuroinflammation-induced neurodegeneration.^[@bibr251-1536012120927609]^

### PET Radioligand of P2Y~12~R {#section22-1536012120927609}

Since P2Y~12~ receptors are the only identified target exclusively expressed on M2-type microglia, PET imaging of this receptor could help detect the precise role of microglial phenotype in each stage of neuroinflammation and identify stages of the neurodegeneration diseases. Thus, an antagonist of P2Y~12~R (sulfonylureas compound 5, with IC~50~ = 6 nM)^[@bibr300-1536012120927609]^ was radiolabeled with ^11^C to produce \[^11^C\]5, as shown in [Figure 9](#fig9-1536012120927609){ref-type="fig"} and used as a PET tracer for evaluation of the P2Y~12~ receptor^[@bibr301-1536012120927609]^ function in MS disease progression.^[@bibr24-1536012120927609],[@bibr302-1536012120927609]^ Unfortunately, \[^11^C\]5 was shown to be an unstable tracer that metabolized rapidly in plasma and in an ex vivo biodistribution study in rats, and only very low brain uptake of this radioligand was detected in this study.^[@bibr302-1536012120927609]^ Therefore, its use for PET imaging of the P2Y~12~ receptor is not favored.

![\[^11^C\]Radiolabeled P2Y~12~R PET ligand \[^11^C\]5. PET indicates positron emission tomography.](10.1177_1536012120927609-fig9){#fig9-1536012120927609}

P2Y~13~ Receptor and Functions in the CNS {#section23-1536012120927609}
-----------------------------------------

P2Y~13~ receptor is one of the most recently identified nucleotide receptor on neurons.^[@bibr303-1536012120927609]^ Like P2Y~1~ and P2Y~12~, P2Y~13~ receptor belongs to a group of P2Y receptors responding to endogenous nucleotides ADP.^[@bibr304-1536012120927609]^ P2Y~13~Rs are specifically present in cerebellar astrocytes, microglia, and granule neurons where they, and not the P2Y~1~ receptors, participate in the ADP-evoked calcium responses with P2Y~13~ expression higher in microglia than in the astrocytes.^[@bibr305-1536012120927609]^ In granule neurons, P2Y~13~ receptors have been coupled to PI3K/Akt pathway that prevents neuronal death.^[@bibr304-1536012120927609]^ Additionally, P2Y~13~-mediated ERK1/2 signaling has shown to trigger activation of CREB, suggesting an antiapoptotic act of the P2Y~13~ receptor against glutamate neurotransmitter toxicity.^[@bibr304-1536012120927609]^ P2Y~13~ receptors are implicated in the release of acetylcholine from synapses and play key roles in neuronal cell differentiation and axonal elongation.^[@bibr305-1536012120927609],[@bibr306-1536012120927609]^

Remarkably, activation of microglial P2Y~12~ and P2Y~13~ receptors following inflammation induces the release of paracrine mediators via upregulation of the P2Y~1~ and P2Y~12~ receptors on proliferated astroglia, and upon reduction of inflammation and microglia phenotype change, both P2Y~12~ and P2Y~13~ have shown to be downregulated on astrocytes.^[@bibr305-1536012120927609]^

While ADP is the known endogenous agonist of P2Y~13~ (EC~50~ = 60 nM),^[@bibr221-1536012120927609]^ 2-MeSADP, a nonselective P2Y~12/13~ agonist, is even more potent at this receptor.^[@bibr271-1536012120927609]^ However, inosine 5′-diphosphate sodium salt (IDP) is the preferential selective P2Y~13~ agonist with 5-fold more potency for hP2Y~13~ over the P2Y~12~ receptor.^[@bibr306-1536012120927609]^ Furthermore, IDP with EC~50~ = 9.2 nM is more potent at murine P2Y~13~ than at human P2Y~13~ (EC~50~ = 552 nM).^[@bibr306-1536012120927609]^ Inosine 5′-diphosphate sodium salt is currently considered as a potent P2Y~13~ receptor agonist.^[@bibr306-1536012120927609]^

Among the P2Y~13~ receptor antagonists, there are some nonselective P2Y~12/13~ antagonist including a highly potent P2Y~12~ antagonist AR-C69931 (IC~50~ = 0.4 nM) and 2-MeSAMP.^[@bibr221-1536012120927609]^ However, nonnucleoside MRS-2211 is a selective antagonist of P2Y~13~ and displays high selectivity over P2Y~1~ and P2Y~12~ receptors.^[@bibr307-1536012120927609]^

P2Y~14~ Receptor and Functions in the CNS {#section24-1536012120927609}
-----------------------------------------

The P2Y~14~ receptor is preferentially expressed in hematopoietic stem cells of both humans and mice.^[@bibr308-1536012120927609]^ While physiological functions of this receptor remain to be established, expression of the P2Y~14~ receptor has been detected in immune cells, suggesting its connotation with inflammation.^[@bibr309-1536012120927609]^ Most of the data on P2Y~14~ is associated with its peripheral effects, but there are indications of its expression in human astrocytes^[@bibr310-1536012120927609]^ and rat cortical and cerebellar astrocytes.^[@bibr311-1536012120927609]^ Increased P2Y~14~ receptor expression in LPS-mediated microglial activation also suggests its role in CNS inflammatory responses.^[@bibr312-1536012120927609]^ In mice, P2Y~14~ deficiency has not shown to carry a noticeable CNS effect under homeostatic conditions, but showed reduced tolerance to glucose and insulin secretion deficiency.^[@bibr313-1536012120927609]^ A variety of factors including aging, radiation therapy, consecutive exposure to chemotherapy, and repeated bone marrow transplantation have shown to increase senescence in animals lacking P2Y~14~ receptor.^[@bibr314-1536012120927609]^

Therapeutic effect of the P2Y~14~R activation on CNS diseases are not fully elucidated yet. The P2Y~14~R is activated by UDP-glucose (EC~50~ = 80 nM).^[@bibr221-1536012120927609]^ This endogenous ligand is not prone to hydrolysis and acts as an extracellular pro-inflammatory mediators.^[@bibr315-1536012120927609]^ UDP also acts as a P2Y~14~ R agonist, overlapping with the P2Y~6~R. Several analogs of UDP including MRS2802 and MRS2905 have exhibited high potency and selectivity at the P2Y~14~ over the P2Y~6~ and other P2Y receptors.^[@bibr316-1536012120927609]^ Releases of nucleotide-sugars in astrocytes play an important role in maintaining the normal status of the cell via P2Y~14~ receptors.^[@bibr317-1536012120927609]^

Potential P2Y~14~R antagonists are dihydropyridopyrimidine base compound with analogs acting as noncompetitive antagonists of the receptor.^[@bibr318-1536012120927609]^ Another set of P2Y~14~ R antagonists are naphthoic acid and derivatives that inhibited \[^3^H\]UDP binding to the P2Y~14~R, suggesting orthosteric antagonism for P2Y~14~ receptors.^[@bibr319-1536012120927609]^ A selective and highly potent competitive antagonist PPTN that was converted to a prodrug has shown to increase bioavailability allowing further studies of this receptor.^[@bibr320-1536012120927609]^ PPTN has shown to inhibit chemotaxis of human neutrophils in cell line expressing P2Y~14~ receptor.^[@bibr320-1536012120927609]^ An analog of Alexa Fluor 488 (AF488), MRS4174 has also exhibited selectivity and a remarkably high binding activity of 80 pM at the P2Y~14~R.^[@bibr320-1536012120927609]^ There has been no report of any PET radioligand for mapping of the P2Y~14~Rs.

Concluding Remarks {#section25-1536012120927609}
==================

Existing evidences indicate that chronic inflammation mediated by modulation of neurons and activation of microglia and astrocytes plays significant roles in CNS disorders and specifically in neurodegenerative diseases. Decades of research toward the discovery and development of treatments for these diseases, especially the neurodegeneration, while successful to some extent, still faces hurdles. The probability that some failed therapies have engaged wrong targets might be a possible explanation. Preclinical findings suggest that elucidation of target engagement of drugs in CNS disorders via PET imaging of the known brain biomarkers can assist to track disease progression, guide drug development, and monitor therapies for the treatment of these disorders. This task requires having access to the number of receptor-selective molecular probes. Especially in early stage of neurodegenerative diseases, in addition to evaluation of cerebrospinal fluid and plasma samples of an individual, PET imaging of pro-inflammatory biomarker of the same individual may help identify the causes of inflammation and potentially assist developing an efficient translational application of relevant therapeutic interventions. Purinergic receptors present promising potential for PET imaging of the neurological disorder biomarkers. These receptors have experienced an exciting journey since the discovery of their first member in early 20th century. Currently, a number of ^11^C and ^18^F PET radioligands of the adenosine, particularly the A~1~ and A~2A~ receptors, and the fast synaptic P2X receptor subtypes, in particular, the P2X~7~ receptor have helped to elucidate the expression and functions of these purinergic receptors in CNS disorders. Despite emerging facts regarding participation of the P2Y signaling in the brain, their functions are not fully recognized. This is largely due to lack of availability of selective nonnucleotide and brain penetrable ligands to be radiolabeled as PET radiotracer for evaluation of their expression and functions in the brain. However, a list of P2Y receptor ligands have been mentioned in this review to enlighten and guide interested scientists in discovering novel PET ligand for noninvasive approach to evaluate the P2Y receptor contribution in the brain disorders and especially the neurodegeneration diseases.
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